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1. Introduction
Critical care medicine is directed toward patients with a wide spectrum of illnesses. These
have the common denominators of marked exacerbation of an existing disease, severe acute
new problems, or severe complications from disease or treatments. In recent years has been
an explosion of evidence based medicine with improvement in outcome, however there are
several conditions in critical care patients that maintains a high morbidity and high mortali‐
ty that is necessary to be addressed [1]. Of these, severe sepsis and the acute respiratory dis‐
tress syndrome (ARDS), including acute lung injury (ALI) (syndromes consisting of acute
respiratory failure associated with pulmonary infiltrates due to intra- or extra-pulmonary
diseases) are two important conditions that have increased mortality in critical care units
around the world [2, 3].
In 1991, a Consensus Conference of the American College of Chest Physicians an the Society
for Critical Care (ACCP-SCCM) introduced the term systemic inflammatory response syn‐
drome (SIRS) as the presence of at least two of four clinical criteria: body temperature more
than 38˚C or less than 36˚C, heart rate more than 90 beats per minute, respiratory rate more
than 20 breaths per minute or hyperventilation with PaCO2 less than 32 mmHg, white blood
cell count more than 12000/mm3, less than 4000/mm3 or with more than 10% immature neu‐
trophils [4]. In 2001, a new consensus suggests that other signs and symptoms could reflect
the clinical response to infection, including: fever/hypothermia, tachypnea/respiratory alka‐
losis, positive fluid balance/edema, general inflammatory reaction, altered white blood
count, increased biomarkers (C-reactive protein, IL-6, pro-calcitonin), hemodynamic altera‐
tions, arterial hypotension, tachycardia, increased cardiac outflow/low systemic vascular re‐
sistance/high venous saturation O2, altered skin perfusion, decreased urine output,
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hyperlactacemia, signs of organ dysfunction, hypoxemia, coagulation abnormalities, altered
mental status, hyperglycemia, thrombocytopenia, disseminated intravascular coagulation,
altered liver function, intolerance to feeding [5].
Systemic inflammatory response syndrome can result from diverse etiologies, including, but
not limited to infectious, trauma, pancreatitis, ischemia-reperfusion injury, and burns [6].
Sepsis is defined as the presence of infection and some of the listed signs and symptoms of
SIRS, whereas severe sepsis is defined as sepsis associated with organ dysfunction and
shock septic as severe sepsis with hypotension, despite adequate fluid resuscitation [7].
Over 18 million cases of severe sepsis occur each year. The number of severe sepsis cases is
set to grow a rate of 1.5% per year from the annual incidence of 3 cases per 1000 of the popu‐
lation in 2001 [8, 9]. Sepsis is a major cause of mortality throughout the world, killing ap‐
proximately 1400 people every day, being as high as an additional fifty per cent as deaths
are often attributed to complications from cancer or pneumonia, and not related to sepsis
[10]. Death is common among sepsis patients, with around 28-50% of patients dying within
the first month of diagnosis [11-13]. Sepsis impacts the lives of many people, including the
patient and their families, in addition to doctors, nursing and care staff. The intense de‐
mands made on hospital staff, equipment and facilities to treat septic patients places a sig‐
nificant burden on healthcare resources, accounting for 40% of total ICU expenditure [10].
Each year the cost of treating septic patients increases and is as high as 7.6 billion euro in
Europe [10] and 17.4 billion euro in the USA [8].
One common complication of SIRS and sepsis is acute lung injury/adult respiratory distress
syndrome (ALI/ARDS). According to a Join North American European consensus commit‐
tee (NAECC), ARDS is defined as an inflammatory process in the lungs with acute onset of
respiratory failure, new bilateral pulmonary infiltrates on frontal chest radiograph or com‐
puted tomography, absence of left ventricular failure (clinically diagnosed or a pulmonary
artery occlusion pressure <18mmHg) and hypoxemia with a ratio between the partial pres‐
sure of arterial oxygen and the fraction of inspired oxygen (PaO2/FiO2 ratio) of ≤27 kPa inde‐
pendent of the level of positive end-expiratory pressure (PEEP) [14]. ALI is defined by the
same criteria except that the PaO2/FiO2 ratio is between 27 kPa and 40 kPa[14-16]. Sepsis is
the most common cause of ALI/ARDS and also the most common cause of death after pa‐
tients develop ALI/ARDS [17]. The incidence of ALI/ARDS is estimated to be 20 to 50 cases
per 100000 person-year, with approximately 18% to 25% of cases meeting oxygenation crite‐
ria for ALI but not for ARDS [18, 19].
The reported rate of mortality from ARDS ranges from 31% to 74% depending on the char‐
acteristics of patients, with most deaths occurring as a consequence of multiple organ failure
and sepsis [18, 19]. ALI has a significant lower crude hospital mortality (32%) compared
with those with ARDS (57.9%) [20]. Crude estimates of the health care costs associated with
ALI/ARDS may exceed 5 billion dollars per year in the United States alone [21].
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2. Physiopathology of sepsis
Microorganisms express macromolecular motifs, named pathogen-associated molecular pat‐
terns (PAMs) such as lipopolysaccharide (LPS), flagellin, double-stranded RNA and CpG
DNA [22]. These molecules are recognized by the immune system through a family of trans-
membrane or intra-cytoplasmic receptors, the pattern recognition receptors (PRRs), classi‐
fied in three general families: a) Toll-like receptors (TLRs); b) NOD-like receptors (NLRs);
and c) RIG-I-like receptors (RLRs) [22].
The TLRs are type I integral membrane glycoproteins characterized by the extracellular do‐
mains containing varying numbers of leucine-rich-repeat (LRR) motifs and a cytoplasmic
signaling domain homologous to that of the interleukin 1 receptor (IL-1R), termed the Toll/
IL-1R homology (TIR) domain [23]. Based on their primary sequences, TLRs can be divides
into several subfamilies, each of which recognized related PAMPs: the subfamily of TLR1,
TLR2 and TLR6 recognize lipids, whereas the highly related TLR7, TLR8, TLR9 recognize
nucleic acids. TLR4 recognize a very divergent collection of ligands [24]. The NLRs proteins
are implicated in the recognition of bacterial components. Proteins in this family possess
LRRs that mediate ligand sensing: a nucleotide binding oligomerization domain (NOD) and
a domain for the initiation of signaling such as CARDs, PYRIN of baculovirus inhibitor of
apoptosis repeat (BIR) domains [25]. The retinoic-acid inducible protein-I (RIG-I) is an INF-
inducible protein containing CARDs and a DExD/H box helicase domain and has been iden‐
tified as a cytoplasmic detector in viral infection in the TLR3 independent manner [26]. In
addition to the numerous exogenous pathogen-derived ligands that activate different TLRs,
endogenous TLR ligands have been identified, including hyaluronic acid, high mobility
group box-1 (HMGB1) and heat shock proteins (HSPs), termed as damaged-associated mo‐
lecular patterns (DAMPs). During tissue injury or proteolysis, extracellular matrix compo‐
nents undergo cleavage, exposing moieties that can act as ligands for TLRs and therefore
initiating TLR-induced signal transduction [27].
The PAM/PPR interaction leads to immune cell activation with initiation of microbe-killing
systems, production and secretion of pro-inflammatory cytokines and chemokines, en‐
hanced expression of co-stimulatory receptors essential for efficient T cell activation, pro‐
duction of arachinoid acid metabolites and initiation of extrinsic coagulation cascade [28-33].
The activation of the TLR signaling originated from the cytoplasmic Toll/IL-1 receptor (TIR)
domain requires the association with the TIR domain-containing adaptor protein, MyD88.
With ligands binding, MyD88 recruits IL-1 receptor-associates kinase-4 (IRAK-4) to TLRs
through interaction of the death domains of both molecules. IRAK-1 activated by phosphor‐
ylation then associates with TRAF6, finally leading to activation of MAP kinases and NFκB.
Additional modes of regulation for these pathways include TRIF-dependent induction of
TRAF6 signaling by RIP1 and negative regulation of TIRAP mediated downstream signaling
by ST2L, TRIAD3A and SOCS1. MyD88-independent pathways induce activation of IRF3
and expression of interferon-β. TIR-domain containing adaptors such as TIRAP, TRIF and
TRAM regulate TLR-mediated signaling pathways by providing specificity for individual
TLR signaling cascades [28-33].
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The interaction of PAMs with NRL recruits the receptor-interacting protein-2 (RIP2) kinase
activating NFκB and MAPK kinases. A number of the NRL molecules have been shown to
form a complex with caspase-1 and the adaptor molecule apoptosis associated speck-like pro‐
tein containing CARD (ASC) termed inflammasome. The central effector molecule of the in‐
flammasome is the cysteine protease caspase-1 that, upon activation cleaves cytosolic pro-
IL-1β, pro-IL-18 and pro-IL-33 to their active forms enabling them to be secreted into the
extracellular/systemic compartments [34]. The important fact is that NRLs and TLRs may syn‐
ergize. T-cell subgroups are modified in sepsis. Helper (CD4+) T-cells can be categorized as
type 1 helper (Th1) or 2 (Th2). Th1 cells generally secrete pro-inflammatory cytokines such as
tumor necrosis factor-α(TNFα) and interleukin-1β (IL-1β); Th2 cells secrete anti-inflammato‐
ry cytokines such as IL-4 and IL-10, depending on the infecting organism, the burden of infec‐
tion and other factors during sepsis may also induce apoptosis of lung and intestinal cells [35].
Activated helper T cells evolve from a Th1 phenotype, producing pro-inflammatory cyto‐
kines, to a Th2 phenotype producing anti-inflammatory cytokines [35]. In addition, apoptosis
of circulating and tissue lymphocytes (B cells and CD4+ T cells) contributes to immunosup‐
pression [36]. The increased pro-inflammatory cytokines, activated B cells and T cells and cir‐
culating glucocorticoid levels causes apoptosis in septic patients [37]. Increased levels of TNF-
α and lipopolysaccharide during sepsis may also induce apoptosis [35].
3. Physiopathology of acute respiratory distress syndrome
There are two general types of ALI/ARDS, direct and indirect. Independent of the initial in‐
sult, the final result is that alveolar-capillary barrier becomes compromised. Direct ALI/
ARDS is often associated with direct mechanical, chemical or infectious stimuli, or other di‐
rect interactions capable to induce damage to lung structures [38]. Indirect pulmonary in‐
sults such as extra-pulmonary sepsis, trauma, shock, pancreatitis, brain injury or massive
transfusion are the mainly causes of indirect ALI/ARDS. However, the highest incidence of
indirect ALI/ARDS is seen during sepsis.
The emigration of activated PMNs and passage through the endothelium in the lungs, one
of the characteristics of ALI, is regulated via adhesion molecules. Among them, L-selectin
(CD62L) on PMNs appears to be involved in the initial rolling proceed on the endothelial
surface, while CD11b/CD18 on PMNs mediate a tighter contact between them. CD31 of PE‐
CAM-1 is needed in the final step for the vascular diapedesis of leukocytes [38-40]. Neutro‐
phils are able to release a variety of harmful substances, such as proteolytic enzymes,
reactive oxygen/nitrogen species, cytokines and chemokynes, which may be injurious to the
adjacent endothelial cell and to the alveoli [39]. PMN apoptosis is a crucial injury-limiting
mechanism of inflammatory resolution. Several inflammatory agents such as LPS, TNF,
IL-8, IL-6, IL-1 and granulocyte colony stimulating factor (G-CSF) can delay apoptotic re‐
sponse, providing PMN with a longer life, allowing accumulating at local tissues [41]. NFκB
has been reported as a modulator of apoptosis in inflammatory cells [42, 43] allowing a pro-
inflammatory state.
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Loss of epithelial cells and endothelial cell injury are involved in pathogenesis of ALI/ARDS.
The former is due to the activation of Fas related apoptosis and the secretion of cytokines
and chemokines by lung epithelial cells [44]. The latter is caused by the interaction of endo‐
thelial cells with neutrophils that stimulate release of vasoactive compounds, increased pul‐
monary vascular resistance with pulmonary hypertension [45], but also endothelial cells can
be directly stimulated by endotoxin via TLR-1 with the release of vasoactive mediators and
molecules altering lung permeability, such as TNFα, thromboxane-A2 and endothelin-1 [46].
Resolution from lung injury is an actively regulated program involving a removal of apop‐
totic neutrophils, remodeling of matrix, clearance of protein-rich alveolar fluid [47]. Recent‐
ly, has been demonstrated that CD4+ lymphocytes as well as plasmacytoid dendritic cells are
active players in this process [48, 49].
4. Vectors for gene therapy
Gene therapy is defined as the introduction of nucleic acids into cells for the purpose of
altering  the  course  of  a  medical  condition o  disease  [50].  In  general,  the  advantages  of
gene therapy over the other treatments are the selective treatment of affected tissues, the
possibility  of  using  locally  endogenous  proteins  in  cases  where  its  systemic  application
would incur in serious adverse secondary effects,  and the possibility of therapeutic long
term after a single application [51]. Currently, there are three categories of gene delivery
methods:  viral  vector  based,  non-viral  vector  based  and  physical  methods  [52].  Viral-
based gene delivery systems is  accomplished by using replication-deficient  viruses  con‐
taining the gene of interest, but with the disease-causing sequences deleted from the viral
genome [53] including RNA-based viral vectors [54, 55], DNA-based viral vectors such as
adenoviral  vectors  [56],  adeno-associated  viruses  (AAV)  vectors  orherpes  simplex  viral
vector  [57].The non-viral  gene delivery methods use synthetic  or  natural  compounds or
physical forces to deliver a piece of DNA into a cell [58]. Two main groups of non-viral
delivery methods have developed: chemical-based, including lipofection [59] and inorgan‐
ic  nanoparticles  that  are  usually  prepared from metals,  inorganic  salts  or  ceramics  [60];
and using physical  forces  such as  local  or  rapid systemic  injection [61],  particle  impact
[62, 63], electric pulse [64] or laser irradiation [65].
5. Gene therapy in sepsis
Currently, there is evidence that applying therapeutic maneuvers such as early effective an‐
tibiotic administration, intensive fluid resuscitation, mechanical ventilation in selected pa‐
tients and use of C activated protein in sickest patients improve significantly the survive in
these patients [66]. There are several clinical studies that are trying to validate another kind
of therapies such as extra-renal depuration, levosimendan, the use of immunoglobulins, ni‐
tric oxide, statins, selenium, the use of enteral nutrition with eicosapentaenoic acid (EPA)/ψ-
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linolenic acid (GLA) that are in progress [67]. Basic research and clinical trials have focused
on alternative therapeutic approaches [68].
5.1. Pattern associated membrane receptors
Different approaches have designed trying to block the interaction between PAMs and
PPRs. One is the generation of antibodies that bind TLRs. Studies conducted with anti-lipo‐
polysaccharide binding protein or anti-CD14 in experimental models of endotoxic shock
and Gram-negative bacterial sepsis, failed to show a protection when treatment was admin‐
istered after LPS o simultaneously with or shortly after bacterial inoculation [69-71]. By us‐
ing a recombinant chimeric fusion protein composed of the N-terminal and central domains
(amino-acids 1-334) of the extracellular part of TLR4 and the Fc portion of the human IgG1,
Roger et al [72] produced an anti-TLR4 antibodies that inhibited LPS-induced intracellular
signaling and cytokine production and protected mice from lethal endotoxic shock and E.
coli bacterial sepsis, not only in pre-treatment with the antibodies, but also even when treat‐
ment was delayed for several hours after endotoxemia of the onset of sepsis.
The RAGEs (receptor for advanced glycation end products) are part of DAMPs that may
play a role in the perpetuation of inflammation that carries to severe sepsis or septic shock.
RAGEs are up-regulated in acute and chronic inflammation and bind multiple endogenous
mediators involved in sepsis and products of oxidative stress [73]. In a recent work, Christa‐
ki et al demonstrated that blocking RAGEs either before or after infection protected mice
from lethality in sepsis due to S. pneumoniae pneumonia [74] probably by indirect inhibition
of NFκB activation.
Exposure to Staphylococcal enterotoxin (SE) or SE plus lipopolysaccharide (LPS, endotoxin)
in mice, triggers vigorous intracellular signaling that leads to hyper-inflammation and re‐
lease of pro-inflammatory cytokines such as TNFα, INFγ, IL-1β, IL-1α, IL-2 and IL-6 by acti‐
vation of innate immunity [75]. In order to evaluate the role of MyD88, the anchor adaptor
protein that integrates and transduces intracellular signals from TLRs and IL-1 receptor su‐
perfamily, Kisssner et al evaluates a synthetic molecule, hydrocinnamoyl-L-valyl-pyrroli‐
dine (Compd1), which mimics the BB-loop in the TIR domain of MyD88. They observed an
inhibited pro-inflammatory cytokine production in human primary cells. Also, administra‐
tion of Compd1 to mice inhibited pro-inflammatory cytokine response and increased surviv‐
al from toxic shock induced death-limiting hyper-inflammation [76].
Recently, the knockdown or TLR2 by three different small interfering RNAs (siRNA) (A: 5’-
aactatccactggtgaaacaa-3’, B: 5’-aaacttgtcagtggccagaaa-3’, C: 5’-aaagtcttgattgattggcca-3’) re‐
duce de tumorigenesis generated by the injection of BEL-7402 cells in an athymic mouse.
Also, the levels of cytokines IL-6 and IL-8 were found to be markedly depressed [77]. In this
line, Lei Ming et al have designed four siRNA:
siRNA-180, 5’-GCCUGGAAUACCUUCUAAATT-3’;
siRNA-224, 5’-GGGCAGUUCACUGAUAUUATT-3’;
siRNA-341, 5’-CAGGAACUGACUCUUGAAATT-3’;
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siRNA-987, 5’-CCCACUCGGAGAAGUUUAATT-3’ against mCD14. In vitro experiments
with RAW264.7 cells (a transformed murine macrophage cell line) shown that siRNA-224 ef‐
fectively inhibited LPS-induced TNFα, MIP-2 and IL-6 release and NO production [78].
5.2. Intracellular signaling
Severely burned patients are greatly susceptible to infection with various pathogens [79].
Macrophages (MΦs) have an important role in antibacterial innate immunity. In methicillin-
resistant Staphylococcus aureus infection (MRSA), MΦs (IL-12- IL-10-) differentiate in two dif‐
ferent subpopulations, M1MΦ (IL-12+ IL-10-) and M2MΦ (IL-12- IL-10+). The former are
converted by the TLRs stimulation and has the ability to kill bacteria, to produce reactive
nitrogen intermediates, and to release antimicrobial peptides [80], playing a pivotal role in
host microbial resistance. M2MΦ have reduced ability to kill bacteria; IL-10 and CCL7 re‐
leased by M2MΦ are inhibitory molecules on the pathogen-stimulated MΦ conversion to
M1MΦ. IL-10 is also a deactivator of antibacterial immunocompetent cells [81] and an inhib‐
itory molecule on various immunocompetent cell functions. Asai et al have demonstrated
that IL-10 antisense oligonucleotides in a severely burned mice prevents the burn associated
conversion of MΦ to M2MΦ and infectious complications stemming for MRSA local infec‐
tion did not develop [82].
CCL2 is a chemokine that attracts and activates mononuclear cells. The necessity of this che‐
mokine for Th2-cell generation has been demonstrated. In a study Shigematsu K et al [83]
tried to protect thermally injured mice orally infected with a lethal dose of E. faecalis by gene
therapy utilizing phosphorothioate-CCL2 antisense oligodeoxynucleotides. They demon‐
strate that sepsis stemming from E. faecalis translocation in severely burned mice is control‐
lable by the gene therapy using CCL2 antisense ODNs, through the elimination of
mesenteric lymph node macrophages (MLN- MΦ)-M2aMΦs and M2cMΦs subtypes. [83].
IL-1β binds the type-1 IL-1 receptor, while LPS binds to TLR4, both activates intracellular
pathways by phosphorylation of IRAK family members including IRAK-1, which involve
the MyD88 adaptor protein [84]. The group of Johns RE et al developed a family of “smart”
polymeric carriers, termed encrypted polymers that enhance the cytoplasmic delivery of
therapeutic antisense oligonucleotides (ASONs). This group has demonstrated that these
ASONs block LPS activation of the transcription factor NFκB reducing the LPS-induced ex‐
pression of cytokines and chemokines. IL-6 shows a 2-fold decrease whereas TNFα expres‐
sion trended to decrease. There was a 2-fold decrease in expression of several genes
including MCP1, MCP3, eotaxin and IP10 [85].
5.3. Apoptosis
Caspases are pro-enzymes of the aspartate-specific cysteine protease family and its activa‐
tion plays a central role in the execution of apoptosis [86]. Depending of the stimuli, two cas‐
pase-activation pathways have been described, the mitochondria-initiated caspase-8-
dependent pathway and mitochondria-initiated caspase-9-mediated pathway. Activation of
these pathways initiates a downstream cascade of effector caspases, such as caspase-3 that
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cleaves substrates such as D4-GDI leading to cell death [87]. The group of Ayala A et al in
2005 demonstrated that suppression of Fas or caspase-8 gene expression with hydrodynamic
administration of siRNA conferred a survival advantage in septic mice model after caecal
ligation and perforation (CLP) [88]. In a work of Matsuda N et al, they examined the thera‐
peutic efficacy of caspase-8 and caspase-3 gene silencing with siRNAs delivered by systemic
injection in a CLP endotoxic shock mouse model. They demonstrate that in vivo delivery of
caspase-8/caspase-3 siRNAs conferred a dramatic survival advantage to CLP mice as com‐
pared to controls. Also they demonstrated that the survival benefit was observed despite ad‐
ministration of siRNA as late as 10h after CLP [88].
BRCA1 is a critical regulator of DNA damage repair and cell survival. In a recent article,
Teoh H et al demonstrated a reduction in 24 hours post caecal ligation and perforation and
thioglycollate stimulation mortality with pretreatment with human BRCA1 adenovirus
(AdBRCA1). Treatment with AdBRCA1, a human adenovirus type-5 (dE1/E3), blunted CLP-
associated cardiac, pulmonary, hepatic and renal dysfunction and also reduced CLP-elicited
double strand breaks and apoptosis in the liver. BRCA1 gene therapy was associated with
lower CLP-evoked cardiac and hepatic superoxide generation that in the liver was in part
due to improved reactive oxygen species removal. CLP also elevated mesenteric arteriolar
and serum intercellular adhesion molecule-1, both of which were partially abrogated with
AdBRCA1 administration. Thioglycollate-challenged AdBRCA1-treated mice displayed re‐
duced peritoneal neutrophil recruitment and dampened cytokine elaboration relative to
their Ad-null-treated counterparts [89].
6. Gene therapy in ARDS/ALI
Over the past 20 years, the feasibility of using gene transfer to treat ALI/ARDS has been
demonstrated using a variety of viral and non-viral vectors to deliver various transgenes to
the lung [90].
6.1. Strategies to increase pulmonary surfactant
ALI/ARDS is a surfactant-deficient state. Pseudomonas aeruginosa infection is a cause of pul‐
monary infection and ARDS with surfactant deficient phenotype. Zhou J et al have demon‐
strated the attenuation of the deleterious effects of Pseudomonas aeruginosa infection by
adenoviral gene transfer overexpressing CCTpenta (a mutant form of the regulatory enzyme
CCTα required for the biosynthesis of dipalmitoyl phosphatidylcholine (DPPC), the major
phospholipid of surfactant) with a significant increase of the biosynthesis of surfactant. This
study suggests that augmentation of DPPC synthesis via gene delivery of CCTα can attenu‐
ate impaired lung function in surfactant-deficient states such as bacterial sepsis [91].
6.2. Strategies to improve pulmonary edema
The physiological hallmark of ARDS is disruption of the alveolar-capillary membrane barri‐
er, leading to development of non-cardiogenic pulmonary edema, in which proteinaceous
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exudate floods the alveolar spaces, impairs gas exchange and precipitates respiratory failure
[92]. Several studies indicate that CLP (cecal ligation and puncture) sepsis model, sepsis and
endotoxemia impair the expression of heat shock protein (HSP-70). Data shown that HSP-70
can limit inflammatory responses protect proteins from damage, restore function to proteins
that are damaged and prevent cellular destruction, key processes of ALI/ARDS [93]. Weiss
et al have demonstrated that the use of an adenoviral vector (AdHSP, an adenovirus carry‐
ing the gene for HSP-70) correcting the relative defect in HSP-70 expression prevents neutro‐
phil accumulation, reduce protein rich edema fluid and improve the outcome in ARDS
secondary to CLP [94].
Injury of the alveolo-capillary barrier alters active Na+ transport, leading to impaired edema
fluid clearance from the alveolar spaces. Failure to return to normal clearance is associated
with poor prognosis [95]. The primary force driving fluid reabsorption from the alveolar
space into the interstitium and the pulmonary circulation is active Na+ transport. Sodium is
taken up on the apical surface of the alveolar epithelium by amiloride-sensitive and -insensi‐
tive Na+ channels [96] and is subsequently pumped out of the cell by the Na+/K+-adenosine
triphosphatase (Na+/K+-ATPase) on the baso-lateral side [96]. Some studies have demonstrat‐
ed the importance of Na+/K+-ATPase in ALI/ARDS. In normal adults rats, overexpression of
the β1-subunit gene by utilizing a replication-incompetent human type-5 adenovirus ex‐
pressing Na+/K+-ATPase-β1 subunit cDNA increased alveolar edema clearance over two-
fold compared with controls [97]. Similarly, gene transfer of the Na+/K+-ATPase-β1 subunit
using electroporation increased alveolar fluid reabsorption [98]. Furthermore, while rats ex‐
posed to 100% oxygen develop ALI and impaired alveolar fluid clearance; overexpression of
the Na+/K+-ATPase-β1 subunit in the alveolar epithelium of rats increased lung liquid clear‐
ance and, most importantly, overexpression of the Na+/K+-ATPase-β1 subunit resulted in
100% survival over 14 days of hyperoxia (compared with 25-31% survival in the non-treated
or null virus-treated control groups) [99].
In this line, Stern M et al used a cationic liposome to transfer cDNA encoding both α and β
subunits of Na+/K+-ATPase to the lung of a mouse model of pulmonary edema induced by
thiourea; they observe a significant resolution of pulmonary edema in vivo. Also, overex‐
pression of the β2-adrenergic receptor leads to increased alveolar fluid clearance in rats by
increasing both membrane-bound amiloride-sensitive Na+-channel expression and Na+/K+-
ATPase function, probably enhancing responsiveness to endogenous catecholamines in the
alveolar epithelium [100].
The regulation of alveolar transport proteins is vital in the maintenance of alveolar fluid bal‐
ance in patients [101]. The exposure to hypoxia results in decreased Na+/K+-ATPase activity
and protein abundance at the plasma membrane by promoting the endocytosis of the pump,
which contributes to a decrease in alveolar fluid reabsorption in both in vivo an ex vivo mod‐
els of hypoxia. Also, the overexpression of the reactive oxygen species scavenger, SOD2,
prevents this hypoxia-mediated decrease in alveolar fluid reabsorption and Na+/K+-ATPase
function [102].
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6.3. Strategies to afford oxidant injury-related injury, apoptosis and inflammation
Keratinocyte growth factor (KGF) is an epithelial-specific growth factor secreted by fibro‐
blast and vascular smooth muscle cells and a main mitogen for alveolar type II cells [103].
Baba et al have demonstrated that transient over-expression of KGF in the lungs attenuate
pathophysiological impairments in hyperoxia-induced acute lung injury by increasing Ki67
and surfactant protein C (Sp-C)-positive cells and proliferation of epithelial cuboidal cells
[104]. There is an abundance of evidence regarding the protective effect of pre-treatment
with KGF on lung injury induced by hyperoxia, acid instillation, radiation, bleomycin, α-
naphthylthiourea, ventilator and bacterial pneumonia there are some studies that supports
the potential clinical application of KGF-2 in the treatment of ALI/ARDS [105].
Human angiopoeitin-1 (ANGPT1), a ligand for the endothelial-restricted receptor TEK tyro‐
sine kinase, plays an essential role in blood vessel maturation and stabilization during em‐
bryonic development. In postnatal, ANGPT1 maintains the normal quiescent phenotype of
vascular ECs, protecting against vascular inflammation reducing permeability and promot‐
ing ECs survival. In a study of Mei SH and co-workers carried out in an ALI mice model (by
intra-tracheal instillation of LPS), they have demonstrated that mesenchymal stem cells
(MSCs) administration alone into the pulmonary circulation partially prevents LPS-induced
lung inflammation. However, cell-based gene transfer using pANGPT1-transfected MSCs
resulted in further improvement in both alveolar inflammation and membrane permeability.
Also, MSCs-pANGPT1 dramatically reduced cytokine levels (IFNγ, TNFα, IL-6 and IL1-β)
to the baseline values observed in naïve mice, suggesting a potential therapeutic approach
to ALI/ARDS [106].
Pearl M and colleagues in a 2005 study using Fas- and caspase-8 siRNA intra-tracheal ad‐
ministration in a CLP mice model of sepsis demonstrated that the main targets of siRNA de‐
livery are the epithelial cells. Also, that down-regulation of Fas but not caspase-8 reduces
pulmonary apoptosis and lung inflammation, decreases neutrophil influx and attenuates
ALI [107].
Overexpression of interleukin IL-10 trough recombinant adeno-associated virus type-5
(AAV5) vector expressing murine IL-10 into pulmonary, tissue proinflammatory cytokines
IL-1β and TNFα, macrophage inhibitory protein-1αand keratinocyte chemoattractant in the
epithelial lining fluid and lung homogenate were decreased and neutrophil infiltration was
less pronounced and more localized neutrophil infiltration in lung section [108].
Finally, Hemoxygenase-1 (HO-1) is an inducible isoform of the first and rate-controlling en‐
zyme of the degradation of heme into iron, carbon monoxide, and biliverdin, the latter being
subsequently converted into bilirubin. Several positive biological effects exerted by this en‐
zyme have gained attention, as anti-inflammatory, antiapoptotic, angiogenic, and cytopro‐
tective functions are attributable to carbon monoxide and/or bilirubin Also, the enzyme has
been involved in controlling infiltration of neutrophils into the injured lung and in the reso‐
lution of inflammation by modulating apoptotic cell death and cytokine expression. Several
groups have delivered HO-1 expressing adenoviruses to the lungs in both pneumonia and
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hyperoxia models and have shown significant reductions in inflammation and subsequent
lung injury [90].
7. Future directions and conclusion
Sepsis and acute lung injury/acute respiratory distress syndrome are important pathologies
in critical care medicine. There are increasing evidence from relevant pre-clinical studies
that support the efficacy of gene-based therapies. Multiple barriers exist to the successful
use of gene therapy in critical care medicine and particularly in sepsis and ALI/ARDS. Fu‐
ture research approaches are necessary to overcome these barriers by developing better viral
and non-viral vectors, enhanced and specific gene expression strategies, improved cellular
uptake of vectors and better therapeutic targets.
Although the treatment by transference of genetic material still presents many challenges,
the technology is rapidly evolving and the possible use in clinical trials could be in a near
future. So, the aim of this chapter was to understand the molecular mechanisms involved in
acute respiratory distress syndrome and sepsis, to review the viral and non-viral gene thera‐
pies that have been developed to improve survival and to address the challenges of gene
therapy in critical care patients using these two life-threating conditions as a model.
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